Clinical trials
Phase 2 Multiple Myeloma trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2005 | 2 |
| 2006 | 4 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Unknown status | 10 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 5 |
| Korean Multiple Myeloma Working Party | 4 |
| GlaxoSmithKline | 3 |
| Samsung Medical Center | 3 |
| Chonnam National University Hospital | 2 |
| Cooperative Study Group A for Hematology | 2 |
| Eli Lilly and Company | 1 |
| Gleneagles Hospital | 1 |
| Kosin University Gospel Hospital | 1 |
| MitoImmune Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 29 |
| Lymphoma | 4 |
| Hematologic Neoplasms | 2 |
| Neoplasms | 2 |
| Recurrence | 2 |
| Amyloidosis | 1 |
| Biliary Tract Neoplasms | 1 |
| Gastrointestinal Stromal Tumors | 1 |
| Glioma | 1 |
| Leukemia | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.